教員業績データベース |
|
論文種別 | 原著 |
言語種別 | 英語 |
査読の有無 | 査読あり |
表題 | Lenvatinib as second-line treatment after atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma -clinical results show importance of hepatic reserve function. |
掲載誌名 | 正式名:Oncology ISSNコード:14230232/00302414 |
掲載区分 | 国外 |
巻・号・頁 | 101(10),pp.624-633 |
著者・共著者 | Hiraoka Atsushi, Hatanaka Takeshi, Kakizaki Satoru, Tada Toshifumi, Hirooka Masashi, Kariyama Kazuya, Tani Joji, Atsukawa Masanori, Takaguchi Koichi, Itobayashi Ei, Fukunishi Shinya, Tsuji Kunihiro, Ishikawa Toru, Tajiri Kazuto, Ochi Hironori, Yasuda Satoshi, Toyoda Hidenori, Ogawa Chikara, Nishimura Takashi, Shimada Noritomo, Kawata Kazuhito, Kosaka Hisashi, Naganuma Atsushi, Yata Yutaka, Tanaka Takaaki, Ohama Hideko, Tada Fujimasa, Nouso Kazuhiro, Morishita Asahiro, Tsutsui Akemi, Nagano Takuya, Itokawa Norio, Okubo Tomomi, Arai Taeang, Imai Michitaka, Koizumi Yohei, Nakamura Shinichiro, Kaibori Masaki, Iijima Hiroko, Kumada Takashi, Hiasa Yoichi. Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan) |
発行年月 | 2023 |